The compounded GLP-1 cliff and what it did to vendor pricing

A pricing floor disappeared

For a stretch, a meaningful share of employer-adjacent GLP-1 programs quietly depended on compounded semaglutide to make their unit economics work. It allowed vendors to advertise all-in pricing that branded therapy could not support, and it let some programs promise access without a serious conversation about pharmacy spend.

As that access narrowed, the vendors most dependent on it faced a straightforward problem: the cost basis underneath their pricing moved, and their contracts did not.

Three responses, three signals

Absorb it. A small number of well-capitalized vendors held pricing and took the margin hit, betting that stability would win renewals. For buyers this is the best short-term outcome, but it is worth asking how long the subsidy can last and what happens at renewal.

Pass it through. Others triggered price adjustment clauses. Unpleasant, but honest — and it revealed which contracts had those clauses in the first place. If you did not know your agreement had one, that is a lesson about contract review, not about the vendor.

Re-route clinically. The most interesting response was protocol change: shifting toward generic and lower-cost agents first, with documented escalation criteria. Vendors that could do this had already built step therapy into their clinical model rather than relying on a cheap supply of the expensive drug.

What buyers should take from it

The episode was a useful stress test of a question that is otherwise hard to answer in diligence: does this vendor have a clinical model, or a sourcing arbitrage?

Ask any prospective vendor directly how their pricing changed through that period and why. The answer separates companies with a durable protocol from companies that were passing along a temporary cost advantage and calling it a program.

It is also a reminder to read your price adjustment clause before you need it. Several buyers discovered theirs by receiving an invoice.